Lumos Pharma, Inc. (LUMO) Tops Q2 EPS by 6c

Lumos Pharma, Inc. (NASDAQ: LUMO) reported Q2 EPS of ($0.65), $0.06 better than the analyst estimate of ($0.71).

“The second quarter continued to be a busy and productive one for Lumos Pharma,” commented Rick Hawkins, Chairman, CEO and President. “Most notably, the efforts of our team during this period culminated in the sale of our Priority Review Voucher in line with our expectations, further strengthening our balance sheet. With a Study May Proceed letter from the FDA in hand, we are progressing toward our goal of initiating the Phase 2b trial of LUM-201, our oral therapeutic candidate for PGHD, prior to the end of this year. In addition, we continue to engage in activities to expand our pipeline through the licensure of other rare disease assets. With our strong balance sheet and non-dilutive funds from the monetization of our PRV, we believe Lumos Pharma is well positioned to execute on our clinical and business development plans.”

For earnings history and earnings-related data on Lumos Pharma, Inc. (LUMO) click here.

You May Also Be Interested In

• Vivos Therapeutics posts 35% revenue gain but widens net loss
• Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c
• Newton Golf Company (NWTG) Reports Q2 Loss of $0.49